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Amyloid-beta Alzheimer targets — protein
processing, lipid rafts, and amyloid-beta pores
Sage C. Arbor*, Mike LaFontaine, and Medhane Cumbay
Marian University College of Osteopathic Medicine, 3200 Cold Spring Road, Indianapolis, IN, 46222
IntroductIon
For decades, the amyloid-beta (Aβ) and tau pro-
teins have been the two leading targets thought to be the
causative agents leading to Alzheimer’s disease (AD)
[1-5]. These two proteins were intensively studied be-
cause of genetic and largely phenotypic observations,
namely extracellular amyloid plaques and intracellular
tau tangles. The fact that these two macroscopic aggre-
gations of protein were observable in individuals suf-
fering from AD now appears to have led the research
field slightly astray.  
Just over 100 years ago, Alois Alzheimer first de-
scribed the pathology and symptoms of dementia that
would come to be called AD. As life expectancy con-
tinues to increase, a growing percentage of the world’s
population will get AD in their lifetime, with 7 percent
of those ages 65 and older, and 40 percent of people 80
and older in industrialized countries being affected [6].
Despite decades of AD research, neither an effective
therapy nor a vaccine has been developed. However, the
wealth of molecular information now known about AD
progression raises hope for therapeutic development in
the next decade.  
Multiple root causes of AD have been proposed
that have varying levels of supporting data behind
them. The amyloid theory — for decades the most
widely accepted paradigm — initially posited that the
extracellular amyloid plaques kill brain cells and are
the causative agent leading to Alzheimer dementia. in
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RevieW
Amyloid beta (Aβ), the hallmark of Alzheimer’s Disease (AD), now appears to be deleterious in its low
number aggregate form as opposed to the macroscopic Aβ fibers historically seen postmortem. While
Alzheimer targets, such as the tau protein, amyloid precursor protein (APP) processing, and immune sys-
tem activation continue to be investigated, the recent discovery that amyloid beta aggregates at lipid rafts
and likely forms neurotoxic pores has led to a new paradigm regarding why past therapeutics may have
failed and how to design the next round of compounds for clinical trials. An atomic resolution understand-
ing of Aβ aggregates, which appear to exist in multiple conformations, is most desirable for future thera-
peutic development. The investigative difficulties, structures of these small Aβ aggregates, and current
therapeutics are summarized in this review.
YALE JOURNAL OF BIOLOGY AND MEDICINE 89 (2016), pp.5-21. 
1995, genetic links leading to early
Onset Familial Alzheimer’s Disease
(eOFAD) were discovered [7,8].
These mutations are in the prese-
nilin gene, a component of γ-secretase
that cleaves the amyloid precursor
protein (APP), releasing the amyloid
peptide to the cytosol, leading to the
formation of amyloid plaques (Figure
1). in mouse models, mutation of the
presenilin gene causes AD-like symp-
toms that could be alleviated through
inactivation of presenilin [9,10]. Mul-
tiple methods have proven efficacious
in reducing amyloid plaques, and
some have been correlated with better
cognitive outcomes [11-13], whereas
others have not [14-16].
All of the available treatments
for AD do not augment the molecu-
lar players that lead to AD, but in-
stead target the downstream players
associated with cognitive deficits.
Three of the four drugs approved by
the Federal Drug Administration are
cholinesterase inhibitors intended to
counter the loss of cholinergic neu-
rons observed in AD patients. The
fourth drug, memantine, is an
NMDA receptor antagonist that is
thought to work by blocking the cy-
totoxic effects of excess extracellu-
lar glutamate on neurons. 
Although symptomatic control by
these agents has been shown to be sta-
tistically significant, their therapeutic
efficacy is far from robust, and the du-
ration of their effects is limited [17]. The low efficacy of
the existing treatments necessitates the development of
agents with the ability to alter or halt the progression of the
disease. Ongoing drug development has focused on several
aspects of AD, and aims to modify the disease. 
Current drug development falls into four major cate-
gories that target: 
1. The metabolic changes and insulin resistance in
neurons observed with AD.
2. The inflammation associated with certain regions
of the brain that are affected in AD.
3. The production of pathological forms of Tau protein.
4. The production, plaque formation, and clearance
of Aβ. 
The best characterized of these approaches, and the
agents that have shown the greatest promise, have been
those that modify Aβ levels.
While both amyloid plaques and tau tangles are
macroscopically visible phenomena that correlate with
AD progression, recent research suggests they may not
be the causative agents of dementia [18,19]. A new
model to fit available data has been put forward in which
it is Aβ pre-plaque monomers or small oligomers that
cause neuronal death, not the aggregated plaque [20,21].
in this model, large amyloid plaques could even inhibit
neuronal death by sequestering the smaller deleterious
amyloid monomers and oligomers. in this light, previ-
ous conclusions about amyloid plaque may be reinter-
preted as correlative instead of causative. Promising
drugs have been shown to decrease amyloid plaque for-
mation and delay cognitive decline; however, this could
be due to decreased soluble amyloid, which in turn
would decrease the formation of plaques. While there is
not yet consensus on the causative agent leading to AD
neuronal death and dementia, inhibiting Aβ aggregation
has been attempted in numerous ways as a therapeutic
target, with mixed results (Table 1). The structure of Aβ
aggregates, their ability to form neurotoxic pores, and
the mechanism and efficacy of how current compounds
target Aβ will be addressed in this review.
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classic Amyloid Precursor Protein modification and cleavage
pathway: The Amyloid Precursor Protein (APP) is cleaved by α, β,
and γ-secretases. β-secretase cleavage of APP leads to amyloid
plaques, whereas α-secretase results in a truncated amyloid protein,
which does not aggregate.
Figure 1
tAu
Neurofibrillary tangles (NFTs) comprised of hyper-
phosphorylated tau protein (τ), in addition to Aß plaques,
are the other hallmark associated with AD. Tau interac-
tions have been reviewed well [22-24]. Although not the
subject of this review, there are interactions between τ-
tangles [25] and Aβ plaques and therefore these interac-
tions will be cursorily covered. Tau -/- neurons were
protected in vitro from Aβ-induced cell death with anti-
bodies to tau delaying motor function impairment and
weight loss in multiple transgenic mouse models [23]. The
link between APP metabolism and tau proteostasis is fur-
ther implicated with the evidence that familial forms of
AD, which exhibit mutated APP or increased levels of
APP, have marked increases in intracellular tau. Recently,
there has been evidence suggesting Aβ and tau interact
synergistically to result in the AD phenotype of neuronal
death. 
Jin et al. recently isolated Aβ dimers from Alzheimer
cortex and showed at sub-nanomolar concentration,
without the presence of Aβ fibrils, the Aβ dimers in-
creased hyperphosphorylated tau, followed by micro-
tubule cytoskeleton disruption and neuritic degeneration
[26]. As the amyloid theory would predict, all of these
effects were modified by: knocking down endogenous
tau, which rescued neuron degeneration; overexpression
of human tau, which intensified the neuronal degenera-
tion; and administration of Aβ N-terminal antibodies,
which prevented cytoskeletal disruption. Furthermore,
synthetic dimers had a similar, albeit reduced, effect as
the natural AD dimers [27,28]. 
The hyperphosphorylated tau forms the hallmark ag-
gregates termed tau tangles, but has also been shown to
have other effects that are deleterious such as binding to 
c-Jun N-terminal kinase-interacting protein 1 (JiP1), caus-
ing it to aggregate in the cell body and impair axonal trans-
port in AD. JiP1 normally binds the kinesin light chain
(KLC) and is involved in the linkage of cargos to the ki-
nesin-i motor complex [1,29,30].
AmyloId Precursor ProteIn (APP)
APP can be post-translationally processed to eventu-
ally create the deleterious Aβ peptides; therefore, thera-
peutic targeting of this protein processing is an attractive
target (Figure 1). Full-length APP also has three isoforms
— APP695, APP751, and APP770 — derived from alter-
native splicing, which has been reviewed well by Zhang et
al. [31]. in summary, the latter two, APP751 and APP770,
have a Kunitz Protease inhibitor (KPi) domain on their
intracellular side [32,33] and have been found at elevated
levels in the brains of those with AD [34], along with in-
creased Aß [35]. 
interestingly, APP is part of a protein family in
mammals with two homologous proteins, APP like pro-
tein 1 (APLP1) and 2 (APLP2), which appear to have
overlapping function as the double deletion of APLP2
and either APP or APLP1 is lethal in mice [36-38]. APP
itself is a transmembrane protein that has both cyto-
plasmic and extracellular cleavage products that are rel-
evant in AD. APP is initially cleaved via α-secretase or
β-secretase, which leads to normal or pathological prod-
ucts, respectively (Figure 1).
Therefore, both α-secretase agonists and β-secre-
tase antagonists could act as Alzheimer therapeutics.
Whether α-secretase or β-secretase cleaves APP, there
is intracellular release of amyloid precursor protein in-
tracellular domain (AiCD). Following α or β cleavage,
γ-secretase cleavage yields extracellular p3 or Aβ, re-
spectively. The in vivo role of p3 has yet to be deter-
mined. While p3 can aggregate into fibers, it is not
stable in smaller oligomers, which may explain why it
does not have the neurotoxic effects of Aβ [39]. Two
major isoforms of Aβ exist, namely Aβ40 and Aβ42.
Aβ42 is the primary amyloidogenic form in AD and by
far the most studied. Therefore, shifting processing to-
ward Aβ40 is considered protective for AD [40-42].
Also, there is a rarer Aβ43 isoform that seems to be even
more detrimental than Aβ42 [43].  
The non-disease function of APP and its cleavage
products remains a debated topic with evidence pointing
to a variety of functions including neuron growth and
synaptogenesis, protein trafficking in neurons, signal
transduction across the membrane [44-46], cell adhesion
[47-49], and calcium metabolism [31]. Despite the current
debate of what the “good” function of non-amyloidogenic
APP is, there has been more clear evidence of a benefit of
shifting from amyloidogenic to non-amyloidogenic path-
ways. The understanding of molecular players involved in
shifting toward non-amyloidogenic processing of APP has
resulted in actionable behavioral modifications.
For example, green tea extract contains epigallocate-
chin gallate (eGCG), which has been shown to increase re-
lease of non-amyloidogenic APP six-fold [50]. One way the
increased eGCG does this is by binding the estrogen re-
ceptor, which increases activation of an α-secretase, namely
ADAM metallopeptidase domain 10 (ADAM10) [51].
ADAM10 increases the non-amyloidogenic pathway by
cleaving APP via an eRα/Pi3K/Akt dependent mechanism
[50]. Numerous endogenous interactions also affect APP
enzymatic cleavage. APP localizes to lipid rafts and its in-
teractions with cholesterol, Apolipoprotein e (Apoe), and
other proteins in the rafts such as the Amyloid beta (A4)
Precusor protein-bvinding family A (APBA) proteins, af-
fect APP processing. All of these interactions have been in-
vestigated as therapeutics targets and are discussed below.
β-secretAse And γ-secretAse
APP is processed into Aβ peptides by the actions of
two proteolytic proteins, β-secreatse and γ-secretase. β-
secretase, also known as β-site APP cleaving enzyme
(BACe), is an aspartyl protease that initiates Aβ peptide
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production [52]. While β-secretase1 is the predominant
form in neural tissue, β-secretase2 isoforms are present
in lower levels and therefore inhibitors of both forms
could be investigated as therapeutic targets [53]. β-sec-
retase1 in particular has been found to have increased
activity in Alzheimer’s patients, as well as those with
mild cognitive impairment that went on to develop AD
[54]. These enzymes are up-regulated in response to cel-
lular stress such as oxidative stress, ischemia, and en-
ergy depletion [29,55]. β-secretase1 is in lipid raft
domains of the cell membrane and requires gly-
cosaminoglycans for effective cleavage [56,57]. 
γ-secretase is a protein complex comprised of at
least four subunits: the enzymatic portion of the com-
plex, presenilin (PSeN) 1 or 2; presenilin enhancer 2
(Pen2);  nicastin (Nct); and anterior pharynx defective-
1 (Aph-1) [58]. These subunits combine in a unique
order to form functional γ-secretase: Nct and Aph-1
first form a dimer, followed by PSeN binding, and fi-
nally Pen2 binding, which may help in PSeN auto-
cleavage [59,60]. More than 50 substrates (such as APP,
Notch, erbB4, and N-cadherin) can be cleaved due to
recognition endowed via Nct and Aph-1 [60-62]. The
fact that γ-secretase activates Notch is problematic in
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that nonselective inhibitors of γ-secretase would have
detrimental side effects. Notch is involved in embryo-
genesis, so potentially women with eOFAD could be
pregnant and unable to use nonspecific γ-secretase in-
hibitors. Notch is also involved in neurogenesis, so
even older patients could have deleterious effects due to
off-target inhibition [63]. 
However, because increased levels of γ-secretase
have been shown to lead to events associated with the
AD pathogenesis [64-67], it continues to be one of the
main targets for the development of therapeutics. PSeNs
contain six to nine transmembrane regions with both
ends in the cytoplasm, and the functional γ-secretase ac-
tually cuts APP in a transmembrane region. The com-
bined actions of β-secretase1 and γ-secretase on APP
lead to the release of Aβ peptides. β-secretase1 cleaves
APP to release a soluble extracellular fragment and a
membrane-bound fragment, C99 [68]. C99 is then
cleaved by γ-secretase at several potential transmem-
brane locations [69], yielding a variety of Aβ peptides
ranging from 39 to 43 amino acids in length.  
FAmIlIAl AlzHeImer dIseAse (FAd)
Familial Alzheimer’s Disease (FAD) is an autoso-
mal dominant condition that represents 5 percent of AD
patients [70], resulting in the development of symptoms
before age 65 [71]. FAD can be caused by mutations af-
fecting three different genes APP, PSeN1, or PSeN2 on
chromosomes 21, 14, and 1, respectively [72,73]. The
mutations on APP all cause up-regulation of Aβ (Aβ40,
Aβ42, or both) through one of three mechanisms: in-
creased APP expression, α-secretase inhibition, or in-
creased activity of β-secretase [71,74-76]. 
Aβ
it is important to note that both the amyloidogenic
and non-amyloidogenic pathways are present in healthy
individuals, with AD presumably being caused through
increased amyloidogenic cleavage or decreased Aβ
turnover [77]. in fact, healthy individuals have Aβ levels
in their plasma and cerebrospinal fluid of 500pM and 3-
8nM, respectively [78,79]. Clots formed in the presence of
Aβ have an abnormal structure and are resistant to clear-
ance. Aβ has been found to bind directly to fibrinogen with
a dissociation constant (kd) of < 7nM, possibly modifying
its tertiary structure and leading to clots [80]. The longer
Aβ digestion fragments are more hydrophobic and asso-
ciated with increased AD risk. Aβ 1-42 has been most ex-
tensively studied due to its abundance in patients
predisposed to AD; however, Aβ 1-43 has been shown to
be even more toxic in both cells and experimental animals
[81]. Mutations in both APP and the PSeNs can influence
which Aβ peptides are formed, and missense mutations in
APP and the presenilins are associated with increased re-
lease of Aβ42 and FAD [82]. 
Aβ structure: WHen, WHere, And WHAt
When does Aß matter — early
The hallmark of Alzheimer’s historically has been
the large extracellular Aß plaques that are seen post-
mortem. if we rewind time from the point of an AD pa-
tient’s death and think about when the Aβ proteins are
doing their damage, it now appears it is many years, even
decades, earlier [83-85]. There is no therapeutic on the
horizon that can reverse the neuronal damage associated
with AD, and because it is such a protracted disease, drug
development is now focused on early stages in the dis-
ease progression. For example, eli Lilly is testing
solanezumab in a Dominantly inherited Alzheimer Net-
work Trial on people ages 65 to 85 who are predisposed
or have been diagnosed with AD, but who have yet to
show clinical symptoms [86]. The recent Aβ structural
insights detailed below suggest that late-stage large Aβ
plaques are not the correct pharmacological target.
Where does Aß matter — lipid rafts
Historically, Aβ was measured as a single entity, not
specifically by the conformation it was adopting. When
measuring Aβ in aggregate, the spatial location of amy-
loid plaques has been found to correlate more strongly
with cognitive impairment [87] than the total volume of
plaque formation [88]. in particular, Aβ levels in the
frontal cortex preceded cognitive decline, while Aβ lev-
els in the entorhinal cortex correlated with measureable
cognitive impairment. While levels of insoluble amy-
loid deposition can differentiate between disease state
and control, only soluble amyloid correlated with meas-
ures of dementia [89].
Protein quantification by western blotting shows a
three-fold increase in soluble Aβ of confirmed AD patients
compared to controls [90]. Again, this fits with the model
where amyloid fibrils are late-stage phenotypes of AD, but
not necessarily causative of dementia, whereas soluble Aβ
is directly deleterious and potentially the starting point of
neuronal death observed in AD. PeT/CT imaging has rap-
idly risen as a useful tool to measure Aβ in vivo with com-
pounds such as monoclonal antibodies (mABs). However,
PeT/CT imagine can be inconsistent in certain organs,
such as the kidney and the heart, and therefore origin of
measurement is an important consideration when com-
paring to normal levels [91-94]. 
Currently, PeT imaging modalities measure total
amyloid. it remains to be seen how finely tuned com-
pounds can detect and differentiate between different
amyloid multimers. A growing area of research has
shifted away from looking at Aβ in extracellular plaques
[42] and instead turned toward the interaction of Aβ in
the plasma membrane, namely direct interactions with
lipid rafts and in β-sheet barrel pore formation [95-103].
Recent evidence has shown Aβ interactions with the
plasma membrane are localized to high cholesterol lipid
rafts domains where Aβ forms Ca+2 channels, thereby
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disrupting membrane function. The localization to lipid
rafts has led to developing therapeutics that target other
proteins localized to lipid rafts, such as those involved in
processing of APP.
cHolesterol
The brain contains 20 percent of the body’s choles-
terol, of which 70 percent is found in the myelin sheaths.
Unlike the rest of the body, essentially all cholesterol in
the brain is unesterified [104,105]. This is important be-
cause almost all of the cholesterol in the brain is synthe-
sized in situ and not transferred from the rest of the body
[106]; therefore, therapeutics targeting cholesterol for AD
patients will have to cross the blood brain barrier to have
their desired effect. The highly polarized nature of neu-
rons causes cholesterol trafficking to be of particular im-
portance as has been well-reviewed elsewhere [107]. 
earlier studies suggested statin use, which inhibits
cholesterol synthesis, was associated with decreased AD
prevalence, but later studies did not support that finding
[108-110]. it has recently been shown by Liu et al. that γ-
secretase cleavage of APP, forming Aβ and AiCD, down-
regulated low-density lipoprotein receptor-related protein
1 (LRP1) by AiCD binding directly to the LRP1 promoter.
LRP1, also known as apolipoprotein e receptor (APOeR),
regulates Apoe and cholesterol levels in the brain, and
therefore could also be a target for AD treatment [111].
Apoe imports cholesterol into neurons via LRP1 and low
activity of LRP1 damages neurons due to low levels of
cholesterol [111]. APP knockouts increased Apoe activ-
ity and increased cholesterol levels. 
The work by Liu et al. connects the two most signif-
icant genetic determinants of AD predisposition, namely
APP and Apoe [112]. Cholesterol has been found to bind
both Aβ and its precursor C99 via a cholesterol-binding
domain (Aβ22-35) [113], with greater affinity for Aβ [113-
115], suggesting another rationale for high cholesterol lev-
els being deleterious. New therapeutics that mimic
cholesterol, such as bexarotene, have been developed that
can compete with cholesterol to bind Aβ and increase Aβ
clearance, but do not initiate pore formation [115].
APoe
Apoe is one of the main apolipoproteins in the brain
and transports both lipids and Aβ. There are three Apoe
variants (Apoe-ε2, Apoe-ε3, Apoe-ε4) with Apoe-ε2
being protective against AD while Apoe-ε4 allele is the
greatest risk factor. Caucasians that are homozygous for
the Apoe-ε4 allele are 15 times more likely to develop AD
[116]. The mechanism for Apoe’s effect in AD is complex
since Apoe is associated with numerous characteristics of
AD, including Aβ plaque formation, τ-tangle formation,
oxidative stress, inflammation, lipid homeostasis deregu-
lation, synaptic plasticity loss and cholinergic dysfunction
[117,118]. Apoe can remove Aβ plaques, with the Apoe-
ε4, Apoe-ε3, and Apoe-ε2 alleles having a low, normal,
and high ability to do so, respectively. 
in patients with AD, Apoe has been found to localize
to senile plaques (polymorphous beta-amyloid protein de-
posits), vascular amyloid, neurofibrillary tangles, and bind
to APP [116,119-121]. Diets high in carbohydrates and
low in essential fatty acids (eFA), especially ω-3 polyun-
saturated fatty acids (PUFAs), increase the risk of devel-
oping AD [122]. One mechanistic hypothesis for the
beneficial effects of PUFAs is that they bind Apoe, which
is the primary ligand for the LDL-receptor and mediates
delivery of lipids across the blood brain barrier (BBB).
The relative efficacies of the Apoe-ε2 and ε4 alleles can
therefore effect cholesterol homeostatis in the CNS [118].
While the BBB protects cholesterol in the brain from
being sequestered by plasma Apoe; 24S-hydroxycholes-
terol can leave the brain crossing the BBB [123]. in fact,
serum and cerebrospinal fluid (CSF) levels of 24S-hy-
droxycholesterol are increased in early AD, which could
be due to increased cerebral cholesterol turnover during
neurodegeneration [124]. While showing mixed results,
there is some evidence for reducing 24S-hydroxycholes-
terol with statin treatment [123]. 
Most recently, both ε3 and ε4 isoforms of Apoe
have been shown to leave the secretory pathway, enter
the nucleus, and directly bind promoters and repress
anti-inflammatory genes such as Sirt1 [125]. Chromatin
immunoprecipitation sequencing (ChiP-seq) results sug-
gest Apoe could interact with as many as ~1,700 gene
promoter regions [125].  
APBAs
The APBAs are a family of adapter proteins
(APBA1, APBA2, and APBA3), previously known as
MiNT 1/2/3 or X11α/β/γ, which are in lipid rafts and in-
volved in protein transport and synaptic function.
APBAs have been found to bind to APP and, although
mixed effects on Aβ production have been reported
[126,127], are generally viewed as lowering deleterious
Aβ production [128-131], which makes them possible
AD therapeutic targets. 
For example, APBA2 phosphorylation by SRC in-
creases APP endocytosis leading to increased nondele-
terious intracellular Aβ production, which was
sequestered in vacuoles [132]. Conversely, APBA2 mu-
tants resistant to phosphorylation increase APP enter-
ing the recycling pathway and were shuttled back to the
cell surface, leading to increases in deleterious Aβ se-
cretion [128,132]. APBAs consist of unique N-termi-
nal regions specific for each isoform, a central
phosphotyrosine binding (PTB) domain and two con-
served, C-terminal postsynaptic density-95/discs
large/zona occludens-1 (PDZ) domains [133]. The PTB
domain interacts with a conserved NPTY (Asn-ProThr-
Tyr) cytoplasmic motif of the APP that participates in
APP trafficking and processing [134]. APBA1 and
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APBA2 interact with other proteins as well, including
Pen1presenilin-1, which is required for γ-secretase ac-
tivity, through the PDZ domain [135]. Surprisingly,
transgenic mice that overproduce Aβ peptides were
found to decrease amyloid plaque production when
crossed with APBA knock-out mice [126]. 
Additional studies have shown that the N-terminus of
APBA contains a Munc18s-interacting (MiD) and
Munc18a domain, that bind and retain APP, and can sup-
press Aβ secretion [136]. The role of APBAs with APP re-
mains complex with APBAs being reported to increase
β-secretase activity [126] and decrease γ-secretase activ-
ity [137], which are the first and second cleavage steps,
respectively, in the amyloidogenic processing of APP to
Aβ (Figure 1). Taken together, these studies suggest that
regulation of APP processing by APBAs is achieved by
interactions with both Pen1presenilin-1 and APP.
GAnGlIosIdes
Another enriched component of lipid rafts is gan-
gliosides, a form of glycosphingolipid containing sialic
acids on the sugar chain. exogenous gangliosides have
been found to elicit multiple neurotrophic effects [138]
and not only help lipid rafts form, but stimulate Aβ pro-
duction, directly bind Aβ, and also increase amyloid
plaques [139-142]. GD3-synthase (GD3S) converts a-se-
ries ganglioside (GM3) to b-series ganglioside (GD3) via
addition of a sialic acid and is thereby the branch point for
a- and b-series gangliosides. This controls the level of a
major b-series ganglioside in the brain, GM1, which
greatly increases Aβ production [143]. 
A negative regulatory feedback loop has recently
been elucidated by Grimm et al. in which GD3 increases
APP cleavage forming Aβ and AiCD, which work via two
mechanisms to synergistically block production of GD3
[139]. Aβ directly binds GM3, reducing the GD3S reactant
pool while increasing the ratio of GM3:GD3, which is an
increase in the overall cell ratio of a-series:b-series gan-
gliosides. AiCD lowers GD3S at a transcriptional level
(via binding the adaptor protein F365) [139]. it is worth
noting that since Aβ is secreted, taken up by cells
[144,145], and present in large concentrations in the cy-
tosol of neurons [40,146,147], Aβ-GM3 binding could
take place along the secretory pathway, in endosomes, by
the cell lipid bilayer, as well as extracellularly [31]. in ad-
dition, while GM3 overall lowers Aβ production, one of its
downstream a-series gangliosides, GM1, has been shown
to have mixed effects by increasing Aβ generation and ag-
gregation in vitro [148], while potentially being neuro-
protective in vivo [149-151].
WHAt conFormAtIon oF Aβ mAtters
The investigation of Aβ aggregates has been greatly
stymied by their lack of rigidity. The Aβ fibrils do not take
on a single conformation, so there is not a single X-ray
crystal structure that represents the only targetable con-
formation. For example, the Asp23-to-Asn mutant of Aβ
(D23N-Aβ1–40), which is associated with eOFAD, can
contain either parallel or antiparallel β-sheets [152,153].
each Aβ peptide can form a β-sheet and two Aβ peptides
can interact forming a β-sheet dimer, which has been
termed a steric zipper. This dimer interaction can be clas-
sified structurally based on three variables: arrangement of
the monomer β-strand internally (parallel or antiparallel),
orientation of β-strands (same edge up for both sheets, or
one up and one down), and orientation of the faces of the
β-sheets (face-to-face [most common], or face-to-back).
All eight of these combined possibilities have been ob-
served experimentally with short peptides [154,155]. ini-
tial investigations suggested the antiparallel fibrils are less
stable and propagate less efficiently, but may nucleate
more efficiently than parallel fibrils. Both antiparallel and
parallel fibrils were found to be cytotoxic [156]. it should
therefore not be surprising that several models for amy-
loid structure have been put forward [157].
For decades, the field had followed large Aβ and tau
aggregates, which it continues to do. indeed the aggre-
gates are correlated with disease progress, with tau ag-
gregates being especially positively correlated with
worsening dementia. it has recently been shown that Aβ
aggregates from two to 12 subunits may be the deleteri-
ous form [114]. in this paradigm, the large amyloids
plaques seen postmortem historically could actually act
as “sinks” to sequester the deleterious Aβ monomers. if
the Aβ sequestering benefit is validated, it could lead to
changes in therapeutic avenues. For example, breaking
up amyloid plaques in an Alzheimer’s patient could be
beneficial. This should only be the case if broken up into
13mers or larger since 3-12mers seem to form toxic
pores. A single amyloid plaque 10,000 Aβ units long has
at most two sequestering ends; if broken up into 100 Aβ
units, it would have 100 times the sequestering power.
in line with this concept, compounds have recently been
discovered that increase Aβ aggregation, yet save cells,
suggesting the Aβ plaques sequestered the more delete-
rious soluble Aβ multimer [18,19].
Aβ AGGreGAtIon
Amyloid plaques created in the lab form multiple struc-
tures dependent on the conditions set. An interesting paral-
lel can be made to the field of crystallography, where
scientists search for just the right buffers to force normally
soluble proteins to form crystal lattices. in contrast, the
amyloid protein is so prone to oligomerization that dis-
cerning the meaningful in vivo structure from the multitude
of in vitro structures has been difficult. A plethora of struc-
tural methods have been used to investigate the dynamic
Aβ aggregation including solution [158] and solid state nu-
clear magnetic resonance (NMR) [159-161], electron para-
magnetic resonance (ePR) [162], cryo-electron microscopy
(cryo-eM) [163,164], atomic force microscopy (AFM)
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[165-167], X-ray [155,168,169] and computational molec-
ular dynamics [170-174] with implicit and explicit water.
investigating these in vitro amyloid aggregates is helpful in
creating therapeutics. 
For example, Agopian et al. [175] formed two signif-
icant amyloid formations of Aβ40, creating an untwisted
conformation if agitated or twisted if not agitated. Both
NMR [176] and ePR [177] work have shown that Aβ fib-
rils form a parallel in-register network in which the same
residues from each monomer pack against each other. it
is worth noting that only a couple of years ago, Liu et al.
described, for the first time, an out-of-register amyloid fib-
ril in which the full complement of hydrogen bonds be-
tween monomers was not formed [178]. Atomic resolution
of the deleterious Aβ oligomer hydrogen bonding network
is vital for rational development of compounds, which will
disrupt this interaction. Since backbone hydrogen bond-
ing of β-sheets always favors planar structure [179], un-
derstanding packing forces that may cause twists in fibrils
is important. Using ePR spectroscopy and 14 spin-labeled
positions, it was found that agitated (untwisted) fibrils had
stronger inter-strand interactions. The two hydrophobic
regions stretching from residues 17-20 and 31-36 had the
strongest interactions with the inter-strand distance esti-
mated to be 0.2Å closer in the untwisted compared to the
twisted fibril [175].
Aβ Pore FormAtIon cAusInG memBrAne
cA+2 conductAnce
One of the most exciting amyloid discoveries, now
two decades old, may be Aβ’s ability to form pores in neu-
rons. Using electrophysiological techniques, Arispe et al.
showed amyloid aggregates form channels in planar lipid
bilayers [180,181]. While it has clearly been shown that
Aβ at millimolar concentrations can cause ion conduction
across the cell membrane [182-186] with a conductivity
of 100pS/pore [187], the exact structural mechanism is de-
bated. Multiple studies have shown Aβ allows Ca+2 in-
flux, which can be blocked by Zn+2 ions [188-190].
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2A,2B: A six-strand ß-
barrel crystal structure
(pdb entry=3SGR),
shown as a membrane
cross-section and ro-
tated 90 degrees look-
ing though the pore,
made of three ß-
sheets. Colored by
strand, each strand
has a tighter ß-sheet
partner on one side
(teal with cyan, yellow
with light orange, red
with dark orange) and
a weaker ß-sheet part-
ner on the other side
(teal with cyan, yellow
with light orange, red
with dark orange).  
Figure 2A: Amyloid ß-barrel 
2A is a cross-section view of the membrane.
2B looks down the barrel of protein pore and
through the membrane.
Figure 2B: Amyloid ß-barrel 
Disruption of calcium channels can cause multisystem dis-
orders collectively, termed “calciumopathies.” 
in the brain, Ca+2 acts as a second messenger to reg-
ulate membrane potential, excitability [191-193], synap-
tic plasticity, and memory encoding [194-197]. Calcium
release from the eR, which has Ca+2 levels multiple or-
ders of magnitude greater than the cytosol, is triggered
by both ryanodine and inositol triphosphate (iP3) recep-
tors, which are activated by cytosolic calcium and iP3,
respectively [198-200]. increased Ca+2 influx into the
cytosol via an Aβ pore leads to increased eR calcium re-
lease, activating eR and mitochondrial stress responses,
which leads to apoptosis [201-205]. 
interestingly, Aβ oligomers administered intracellu-
larly have also been shown to activate eR Ca+2 release
by increasing iP3 even when in a Ca+2 free solution,
hence not related to pore formation [198]. The mechanism
of iP3 stimulation is still being investigated. Several
mechanisms have been presented for this membrane Ca+2
permeability [100], including tension induced poration
[206,207] and disassembly of the lipid bilayer by both
oligomers [96,100], as well as the interaction of the larger
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2c,2d: A 16 ß-strand ß-barrel, shown as a
membrane cross-section and rotated 90 degrees
looking though the pore, composed of eight Aß
subunits, computational modeled by dynamics to
match ssNMR data. The molecular surface is
color coded by hydrophobicity (red = nonpolar,
white = polar, green = cysteine). The images
were made using pymol [231].
Figure 2c
Figure 2d
fibrils with the membrane [208,209]. Aβ pores have been
measured with various numbers of subunits (3-6 Aβ
monomers) by AFM. Most of the pores (two-thirds) are
tetramers or pentamers, with one-third being trimers or
hexamers [210]. Prangkio et al. developed controlled ag-
gregation conditions and used partial least squares (PLS)
to show that oligomers in the 4-13 range promoted both
pore formation and cytotoxicity, while monomers, dimers,
and trimers were negatively correlated with both of these
deleterious outcomes. 
Models of six-stranded β-barrels formed by the last
third of Aβ42 show hydrophobic residues and a glycine in
the core, which is shielded from bulk water by the central
and N-terminus regions, which can adopt both sheet and
helix conformations (Figure-2A-B) [211]. Shafrir et al.
predicted how these antiparallel six-stranded β-barrels in-
teract to form larger fibrils as well without seeing any
large energetic penalties for the transition (animations of
this transition were made available as well) [211]. While
the Aβ β-barrel structure is most easily investigated in sil-
ico, due to its dynamic and membrane bound structure,
the Aβ β-barrel has been investigated at the atomic level
by X-ray [157] and NMR [212]. 
in 2012, a β-barrel compatible with a sequence seg-
ment from Aβ protein was crystallized by eisenberg et al.
at 1.4Å resolution [157]. The structure could not be
solved by molecular replacement with fiber-like struc-
tures and after bromine substitutions, the novel X-ray
structure proved to be a six-stranded antiparallel β-bar-
rel termed cylindrin. each strand in cylidrin has a strong
interface on one side made from 12 hydrogen bonds and
a weak interface on the other side made by eight hydro-
gen bonds (Figure-2A-B).
Computational simulations have been used to suggest
how Aβ pore formation originates. Jang et al. used explicit
solvent molecular dynamics simulations to model 12-, 16-, 
and 20-mer Aβ barrels and had results that were consistent
with solids state NMR (ssNMR). For example, the 16mer
barrel modeled had an outer diameter and pore diameter of
~7.2nm and ~1.6nm, respectively (Fig-2C-D) [212]. it
should be noted these measurements are similar to the 1-
2nm pore size measured by ssNMR, which is physically
wide enough for water to flow through. Unlike the cylin-
drin crystal structure, all β-sheet structures were parallel,
meaning the pore had all β-loops on one side and all N-
and C-terminal ends on the other side. 
Two aspects to note are the pore size opening on each
side and the channels hydrophobicity. The side of the pore
with all β-turns has a smaller opening and a patch of
residues (Glu14, Asp15, and Lys20) from each Aβ pep-
tide, which forms a hydrophilic ring. On the opposite side
of the pore, made of the N- and C-terminal ends, the
residues Glu7 and Lys8 form a hydrophilic ring (shown
as white in Fig2D). The peptide chain in these structures
would be termed “coil” in a normal protein, but are in a
pre-β-sheet layout and represent a possible early stage of
pore formation (Fig-2C-D) [212]. 
Regular antiparallel β-barrels come in two flavors as
defined by their shear number (S) with a higher number
indicating greater displacement between the edges of β-
sheets, slope of strands in degrees (D) relative to the cen-
tral axis of the barrel, and the number of hydrogen bonds
(H) on each side of the β-strands, which may alternate.
Normal β-barrels have either [S=12,D=56º,H=10,8] or
[S=6,D=37º,H=10,10]. Cylindrin shares aspects from both
of these groups with a topology [S=6,D=35º,H=12,8]
[157]. While Aβ pores have been modeled with multiple
sheets, and even with α-helical structures [113], the six-
strand model X-ray model is useful for binding, folding,
and modeling purposes.
current tHerAPeutIc AttemPts, 
successes, And FAIlures
Attempts to decrease Aβ levels have been attempted
for over two decades, however even when effective, the
side effects have proven too deleterious compared to lit-
tle or no cognitive benefit. The first attempt at modify-
ing Aβ levels was performed using immunization with a
synthetic full-length peptide. Although this approach had
shown robust effects in animal studies, and lowered total
Aβ levels in the brains of human subjects, an accompa-
nying T-lymphocyte mediated meningoencephalitis
halted further development [213,214]. Current vaccina-
tion approaches have reduced T-lymphocyte activation
by using an attenuated form of Aβ (Aβ-1-6) [215]. The
development of many Aβ vaccines were terminated after
phase ii clinical trials because they showed low clinical
efficacy. CAD106, which consists of multiple copies of
Aβ1-6, has been shown to consistently increase Aβ-anti-
body titer, without inducing T-lymphocyte activation
[216]. The safety profile of CAD106 suggests that it
could be a potential therapeutic option for AD, but its
clinical efficacy has yet to be determined. 
The leading approach in developing agents that lower
Aβ levels is passive immunity. Animal studies, in which
systemic administration of anti-Aβ antibody was shown
to cross the blood brain barrier and induce an immune re-
sponse to Aβ were the first studies to show the effective-
ness of passive immunity [217]. These initial studies lead
to the development of an humanized anti-Aβ antibody,
bapineuzumab [218]. Bapineuzumab binds to the soluble
and fibrillar forms of Aβ and is well-tolerated at doses less
than 2mg/Kg [219]. in phase iii studies of mild to mod-
erate dementia associated with AD, bapineuzumab was
shown to decrease total brain Aβ load, compared with
placebo control, using positron-emission tomography, but
did not significantly improve cognitive or functional out-
comes as measured by the Alzheimer’s Disease Assess-
ment Scale and Disability Assessment for Dementia [220]. 
A number of other anti-Aβ antibodies have been de-
veloped that target different regions and forms of Aβ
(Table 1) [221]. Unlike bapineuzumab, solanezumab is a
monoclonal antibody that recognizes the soluble
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monomeric, but not the fibrillar, form of Aβ. By interact-
ing with the soluble form of Aβ, solanezumab is thought
to block the more neurotoxic form of Aβ [222]. in a mul-
ticenter phase iii trial with 2,052 patients with mild to
moderate AD, no improvement in cognition or functional
ability was observed in subjects receiving 400mg of
solanezumab every four weeks for 18 months when com-
pared with the placebo group [223]. However, a subgroup
analysis showed a reduction in decline of cognition in the
group with mild AD [221]. Similarly, crenezumab, an anti-
Aβ antibody that binds to both the soluble and fibrillar
forms of Aβ, also seems to be efficacious, although not
robust, in patients with mild AD, but not in those with
moderate AD [224]. The clinical effectiveness of these
agents in the early stages of AD, despite the reduction in
Aβ levels, suggests that the effectiveness of disease-mod-
ifying agents may depend on when they are employed. An
effective AD treatment will likely need to use strategies
to identify early stages of the disease, potentially before
symptoms of the disease begin to manifest, in addition to
the disease-modifying agent. 
Blocking the production of Aβ, by modifying the pro-
cessing of APP, is another strategy for lowering Aβ lev-
els. The target of this approach has been the enzyme
β-secretase. initially, most of the inhibitors were peptide-
based, but ongoing work has focused on small molecule
inhibitors [225]. Development of β-secretase inhibitors is
in its early stage, and to date, only two drugs (MK-8931
and AZD3293) that inhibit β-secretase activity, and thus
reduce the production of Aβ, have reached phase iii clin-
ical trials. MK-8931 and AZD3293 have been shown to
be effective in lowering Aβ levels and are well tolerated
[225,226]. The clinical efficacy of β-secretase inhibitors is
still being determined, but like antibodies that lower Aβ,
β-secretase inhibitors are likely to be more effective in the
early stages of AD. 
conclusIons And outlook
The dynamic and numerous binding interactions of
the Aβ peptide has slowed Alzheimer’s research for
decades. While there is still not a single accepted
causative, structurally characterized, and targetable Aβ
protein structure, there are a number of leading candidates
being pursued. The Aβ pore formed by six (or more) β-
strands has been computationally predicted by multiple
groups and fits experimental evidence, such as AFM im-
ages. Compounds that prevent the pore formation, fol-
lowed by Ca+2 influx into the cytosol, followed by Ca+2
efflux from the eR into the cytosol, could halt neuronal
death and associated cognitive decline. Likewise, new tar-
gets that disrupt lipid rafts, where Aβ localizes, could
delay onset of disease (as has already been shown with in-
creased ω-3 fatty acids [227-230]). Following the effect
of new therapeutics on lipid raft formation and calcium
flux should provide finer resolution of cellular progres-
sion during Alzheimer’s at the molecular level.
Unfortunately, despite all of this recent Aβ structural
elucidation suggesting new avenues for targets, it needs
to be noted that many historically failed therapeutics
should have proven effective if the Aβ pore were the
causative agent. The monoclonal antibodies to Aβ (e.g.
solanezumab, bapineuzumab, and crenezumab) could
have been detecting the wrong conformation of Aβ,
namely monomers or fibrils. However, both β–secretase
and γ–secretase drugs designed to lower the total amount
of Aβ still seem like they should have proven effective.
Developing compounds that can differentiate and detect
the difference between multimers of Aβ will likely prove
very difficult. Such compounds could inherently require
large surface contacts to be able to differentiate. For ex-
ample, if tetramers and octomers had the same repeating
structure and only differed in their size, a compound to
recognize the octomer as different would have to be at
least a little bit longer than the tetramer to detect the
higher multimer of Aβ.
The Alzheimer’s research field is therefore again left
in a situation it has become all too familiar with: learning
more about the disease without an overwhelming obvious
best path forward.  
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